NOVARTISCAREERSINVESTORSOUR COMPANYOUR FOCUSOUR IMPACTOUR SCIENCE Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients

worldwide.

NOVARTIS ANNOUNCES TABRECTA® FIRST PUBLISHED OVERALL Tabrecta ® (capmatinib) showed a median overall survival (OS) of 20.8 months in treatment-naïve patients and 13.6 months in previously-treated patients in first published mature data 1,2; Tabrecta achieved 65.6% overall response rate (ORR) in first-line and 51.6% in second-line settings in new expansion cohort analysis of additional patients 1,2; Patient-reported outcomes on quality-of-life NIBR SCIENCE OF THERAPEUTICS SYMPOSIUM NIBR Science of Therapeutics Symposium: Coronavirus Antivirals, June 8, 2021. The NIBR Science of Therapeutics (NSofT) Symposium aims to bring interested members of the scientific community together in the spirit of open science. The virtual event will feature keynotes and talks by experts from industry and academia around a common theme, with the goal of sharing ‘hard core’ science for NOVARTIS ANNOUNCES POSITIVE RESULT OF PHASE III STUDY WITH Phase III VISION study with 177 Lu-PSMA-617 met both primary endpoints, significantly improving overall survival (OS) and radiographic progression-free survival (rPFS) in patients with PSMA-positive metastatic castration-resistant prostate cancer 1; VISION trial findings to be presented at upcoming medical meeting, with regulatory submissions in the US and EU anticipated in 2021 NOVARTIS LIGELIZUMAB (QGE031) RECEIVES FDA BREAKTHROUGH Ligelizumab is the first treatment to receive FDA Breakthrough Therapy designation in chronic spontaneous urticaria (CSU) in patients with an inadequate response to H1-antihistamines 1; Currently there are limited approved therapies for patients NOVARTIS ANNOUNCES IPTACOPAN MET PHASE II STUDY PRIMARY Phase II primary endpoint results for investigational iptacopan in IgAN demonstrated effective and clinically meaningful reduction of proteinuria 1 – a key risk predictor in kidney disease progression 2; Iptacopan also showed a trend toward stabilization of kidney function 1; Phase III clinical trial APPLAUSE is underway; There are no currently approved treatments for IgAN – a rare and WE ARE UNBOSSING OUR PEOPLE We aim to unlock our leaders to be their best selves. Supporting them to become more self-aware, set clear goals and remove barriers to unleash the power, passion and talent within all of our people including themselves. Our Unbossed Leadership Experience (ULE) guides leaders through the process of self-discovery and deep personal

growth.

NOVARTIS TO UNVEIL NEW DATA AT ASCO AND EHA FROM ITS Overall survival and radiographic PFS from phase III study of investigational radioligand therapy 177 Lu-PSMA-617 VISION trial of patients with metastatic castration-resistant prostate cancer to be presented at ASCO plenary; New Kisqali (ribociclib)* overall survival data from extended follow-up of MONALEESA-3 trial in patients with postmenopausal HR+/HER2- advanced or metastatic breast cancer NOVARTIS REPORTS ONE YEAR RESULTS OF PHASE III MERLIN Beovu (brolucizumab) met MERLIN’s primary endpoint of non-inferiority in change in best corrected visual acuity from baseline and superiority on anatomical secondary endpoints at year one versus aflibercept when given every four weeks following the loading phase 1; In this study evaluating every four week dosing, Beovu was associated with higher rates of IOI including retinal vasculitis and KESIMPTA AND VACCINES KESIMPTA AND VACCINES Vaccine and vaccine-related information from the KESIMPTA Prescribing Information and pivotal trials INDICATION KESIMPTA is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, NOVARTISCAREERSINVESTORSOUR COMPANYOUR FOCUSOUR IMPACTOUR SCIENCE Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients

worldwide.

NOVARTIS ANNOUNCES TABRECTA® FIRST PUBLISHED OVERALL Tabrecta ® (capmatinib) showed a median overall survival (OS) of 20.8 months in treatment-naïve patients and 13.6 months in previously-treated patients in first published mature data 1,2; Tabrecta achieved 65.6% overall response rate (ORR) in first-line and 51.6% in second-line settings in new expansion cohort analysis of additional patients 1,2; Patient-reported outcomes on quality-of-life NIBR SCIENCE OF THERAPEUTICS SYMPOSIUM NIBR Science of Therapeutics Symposium: Coronavirus Antivirals, June 8, 2021. The NIBR Science of Therapeutics (NSofT) Symposium aims to bring interested members of the scientific community together in the spirit of open science. The virtual event will feature keynotes and talks by experts from industry and academia around a common theme, with the goal of sharing ‘hard core’ science for NOVARTIS ANNOUNCES POSITIVE RESULT OF PHASE III STUDY WITH Phase III VISION study with 177 Lu-PSMA-617 met both primary endpoints, significantly improving overall survival (OS) and radiographic progression-free survival (rPFS) in patients with PSMA-positive metastatic castration-resistant prostate cancer 1; VISION trial findings to be presented at upcoming medical meeting, with regulatory submissions in the US and EU anticipated in 2021 NOVARTIS LIGELIZUMAB (QGE031) RECEIVES FDA BREAKTHROUGH Ligelizumab is the first treatment to receive FDA Breakthrough Therapy designation in chronic spontaneous urticaria (CSU) in patients with an inadequate response to H1-antihistamines 1; Currently there are limited approved therapies for patients NOVARTIS ANNOUNCES IPTACOPAN MET PHASE II STUDY PRIMARY Phase II primary endpoint results for investigational iptacopan in IgAN demonstrated effective and clinically meaningful reduction of proteinuria 1 – a key risk predictor in kidney disease progression 2; Iptacopan also showed a trend toward stabilization of kidney function 1; Phase III clinical trial APPLAUSE is underway; There are no currently approved treatments for IgAN – a rare and WE ARE UNBOSSING OUR PEOPLE We aim to unlock our leaders to be their best selves. Supporting them to become more self-aware, set clear goals and remove barriers to unleash the power, passion and talent within all of our people including themselves. Our Unbossed Leadership Experience (ULE) guides leaders through the process of self-discovery and deep personal

growth.

NOVARTIS TO UNVEIL NEW DATA AT ASCO AND EHA FROM ITS Overall survival and radiographic PFS from phase III study of investigational radioligand therapy 177 Lu-PSMA-617 VISION trial of patients with metastatic castration-resistant prostate cancer to be presented at ASCO plenary; New Kisqali (ribociclib)* overall survival data from extended follow-up of MONALEESA-3 trial in patients with postmenopausal HR+/HER2- advanced or metastatic breast cancer NOVARTIS REPORTS ONE YEAR RESULTS OF PHASE III MERLIN Beovu (brolucizumab) met MERLIN’s primary endpoint of non-inferiority in change in best corrected visual acuity from baseline and superiority on anatomical secondary endpoints at year one versus aflibercept when given every four weeks following the loading phase 1; In this study evaluating every four week dosing, Beovu was associated with higher rates of IOI including retinal vasculitis and KESIMPTA AND VACCINES KESIMPTA AND VACCINES Vaccine and vaccine-related information from the KESIMPTA Prescribing Information and pivotal trials INDICATION KESIMPTA is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, NOVARTIS GENE THERAPIES Novartis Gene Therapies is committed to developing and commercializing gene therapies for patients and families devastated by rare neurological genetic diseases. Imagine what you could bring to Novartis Gene Therapies. Learn More. Job Candidates.

CAREERS | NOVARTIS

International Careers. Novartis is committed to supporting our personal growth. Helping us and our families to relocate for an international career or for a development opportunity are just two ways in which we are supported. International Careers. International

Careers.

CAREER SEARCH

Novartis Gene Therapies, GTx (formerly AveXis) has had one focus; to bring change to those devastated by rare and life-threatening genetic neurological diseases. Gene Therapy roles can be found across Novartis and within the dedicated GTx team. For gene therapy roles in Novartis,

free text search

NOVARTIS GLOBAL PIPELINE Novartis Global Pipeline. Benefitting from our continued focus on innovation, Novartis has one of the industry’s most competitive pipelines with more than 200 projects in clinical development. Many of these projects, which include new molecular entities as well as additional indications and different formulations for marketed

products, are

NOVARTIS CARDIOVASCULAR UPDATE Entresto® (titrate to 200 mg bid; dose adjustment permitted) Ramipril (titrate to 5 mg bid; dose adjustment permitted) Screen Randomize between 12hrs up to 7 days after an AMI Wk1 2 Month 1 Month 2 Month 4 Month 8 Month 12 Month 16 Month 20

OPHTHALMOLOGY

Learn how innovative ophthalmology research at Novartis is producing therapies that treat retina diseases, glaucoma, presbyopia, dry eye, ocular surface diseases, other external eye diseases and inherited

retinal diseases.

NOVARTIS REPORTS ONE YEAR RESULTS OF PHASE III MERLIN Beovu (brolucizumab) met MERLIN’s primary endpoint of non-inferiority in change in best corrected visual acuity from baseline and superiority on anatomical secondary endpoints at year one versus aflibercept when given every four weeks following the loading phase 1; In this study evaluating every four week dosing, Beovu was associated with higher rates of IOI including retinal vasculitis and NOVARTIS INVESTIGATIONAL ORAL THERAPY IPTACOPAN (LNP023 Paroxysmal nocturnal hemoglobinuria (PNH) is a rare and life-threatening blood disorder, resulting in debilitating symptoms that can impact patients’ quality of life 1–3; C3 glomerulopathy (C3G) is a rare renal disease, affecting young patients with a poor prognosis and significant unmet need 4-5; With potential to be the first oral treatment for a range of complement-driven diseases HOMEPAGE | NOVARTIS BIOME The Novartis Biome was created as a bridge to help our partners become an extension of our own teams, working with us as easily and productively as possible to jointly innovate and co NOVARTIS AND MOLECULAR PARTNERS ANNOUNCE START OF EMPATHY Michael Meo US External Engagement, Novartis +1 862 274 5414 Julie Masow Novartis US External Communications +1 862 579

8456

NOVARTISCAREERSINVESTORSOUR COMPANYOUR FOCUSOUR IMPACTOUR SCIENCE Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients

worldwide.

NOVARTIS GENE THERAPIES Novartis Gene Therapies is committed to developing and commercializing gene therapies for patients and families devastated by rare neurological genetic diseases. Imagine what you could bring to Novartis Gene Therapies. Learn More. Job Candidates. NOVARTIS ANNOUNCES POSITIVE RESULT OF PHASE III STUDY WITH Phase III VISION study with 177 Lu-PSMA-617 met both primary endpoints, significantly improving overall survival (OS) and radiographic progression-free survival (rPFS) in patients with PSMA-positive metastatic castration-resistant prostate cancer 1; VISION trial findings to be presented at upcoming medical meeting, with regulatory submissions in the US and EU anticipated in 2021 NOVARTIS IN SOCIETY ESG REPORT 2020 The Novartis in Society ESG Report details progress on environmental, social and governance topics and demonstrates the company’s commitment in global health and corporate responsibility. NOVARTIS CARDIOVASCULAR UPDATE Entresto® (titrate to 200 mg bid; dose adjustment permitted) Ramipril (titrate to 5 mg bid; dose adjustment permitted) Screen Randomize between 12hrs up to 7 days after an AMI Wk1 2 Month 1 Month 2 Month 4 Month 8 Month 12 Month 16 Month 20 NOVARTIS REPORTS ONE YEAR RESULTS OF PHASE III MERLIN Beovu (brolucizumab) met MERLIN’s primary endpoint of non-inferiority in change in best corrected visual acuity from baseline and superiority on anatomical secondary endpoints at year one versus aflibercept when given every four weeks following the loading phase 1; In this study evaluating every four week dosing, Beovu was associated with higher rates of IOI including retinal vasculitis and NOVARTIS LIGELIZUMAB (QGE031) RECEIVES FDA BREAKTHROUGH Ligelizumab is the first treatment to receive FDA Breakthrough Therapy designation in chronic spontaneous urticaria (CSU) in patients with an inadequate response to H1-antihistamines 1; Currently there are limited approved therapies for patients WE ARE UNBOSSING OUR PEOPLE We aim to unlock our leaders to be their best selves. Supporting them to become more self-aware, set clear goals and remove barriers to unleash the power, passion and talent within all of our people including themselves. Our Unbossed Leadership Experience (ULE) guides leaders through the process of self-discovery and deep personal

growth.

NOVARTIS AND MOLECULAR PARTNERS ANNOUNCE START OF EMPATHY Michael Meo US External Engagement, Novartis +1 862 274 5414 Julie Masow Novartis US External Communications +1 862 579

8456

BASE E12 - NOVARTIS

Metis. If you are using a basic mobile phone then click one of the below links to download the application. For MobileE12.jad. For

MobileE12MIDP1.jad

NOVARTISCAREERSINVESTORSOUR COMPANYOUR FOCUSOUR IMPACTOUR SCIENCE Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients

worldwide.

NOVARTIS GENE THERAPIES Novartis Gene Therapies is committed to developing and commercializing gene therapies for patients and families devastated by rare neurological genetic diseases. Imagine what you could bring to Novartis Gene Therapies. Learn More. Job Candidates. NOVARTIS ANNOUNCES POSITIVE RESULT OF PHASE III STUDY WITH Phase III VISION study with 177 Lu-PSMA-617 met both primary endpoints, significantly improving overall survival (OS) and radiographic progression-free survival (rPFS) in patients with PSMA-positive metastatic castration-resistant prostate cancer 1; VISION trial findings to be presented at upcoming medical meeting, with regulatory submissions in the US and EU anticipated in 2021 NOVARTIS IN SOCIETY ESG REPORT 2020 The Novartis in Society ESG Report details progress on environmental, social and governance topics and demonstrates the company’s commitment in global health and corporate responsibility. NOVARTIS CARDIOVASCULAR UPDATE Entresto® (titrate to 200 mg bid; dose adjustment permitted) Ramipril (titrate to 5 mg bid; dose adjustment permitted) Screen Randomize between 12hrs up to 7 days after an AMI Wk1 2 Month 1 Month 2 Month 4 Month 8 Month 12 Month 16 Month 20 NOVARTIS REPORTS ONE YEAR RESULTS OF PHASE III MERLIN Beovu (brolucizumab) met MERLIN’s primary endpoint of non-inferiority in change in best corrected visual acuity from baseline and superiority on anatomical secondary endpoints at year one versus aflibercept when given every four weeks following the loading phase 1; In this study evaluating every four week dosing, Beovu was associated with higher rates of IOI including retinal vasculitis and NOVARTIS LIGELIZUMAB (QGE031) RECEIVES FDA BREAKTHROUGH Ligelizumab is the first treatment to receive FDA Breakthrough Therapy designation in chronic spontaneous urticaria (CSU) in patients with an inadequate response to H1-antihistamines 1; Currently there are limited approved therapies for patients WE ARE UNBOSSING OUR PEOPLE We aim to unlock our leaders to be their best selves. Supporting them to become more self-aware, set clear goals and remove barriers to unleash the power, passion and talent within all of our people including themselves. Our Unbossed Leadership Experience (ULE) guides leaders through the process of self-discovery and deep personal

growth.

NOVARTIS AND MOLECULAR PARTNERS ANNOUNCE START OF EMPATHY Michael Meo US External Engagement, Novartis +1 862 274 5414 Julie Masow Novartis US External Communications +1 862 579

8456

BASE E12 - NOVARTIS

Metis. If you are using a basic mobile phone then click one of the below links to download the application. For MobileE12.jad. For

MobileE12MIDP1.jad

MEET NOVARTIS MANAGEMENT 2020 Meet Novartis Management 2020. Annual meeting highlights progress on the company’s transformation and growth strategy. Nov 24, 2020. This annual event gives investors and industry analysts an opportunity to meet with Novartis executives who share deep insights into the company’s growth, pipeline and strategy. NOVARTIS LIGELIZUMAB (QGE031) RECEIVES FDA BREAKTHROUGH Ligelizumab is the first treatment to receive FDA Breakthrough Therapy designation in chronic spontaneous urticaria (CSU) in patients with an inadequate response to H1-antihistamines 1; Currently there are limited approved therapies for patients NOVARTIS REINFORCES COMMITMENT TO PATIENT ACCESS, PRICING Novartis reinforces commitment to patient access, pricing a EUR 1.85 billion sustainability-linked bond NOVARTIS CARDIOVASCULAR UPDATE Entresto® (titrate to 200 mg bid; dose adjustment permitted) Ramipril (titrate to 5 mg bid; dose adjustment permitted) Screen Randomize between 12hrs up to 7 days after an AMI Wk1 2 Month 1 Month 2 Month 4 Month 8 Month 12 Month 16 Month 20 NOVARTIS RECEIVES FDA FAST TRACK DESIGNATION FOR Novartis today announced that the US Food and Drug Administration (FDA) has granted fast track designation for sabatolimab (MBG453) for the treatment of adult patients with myelodysplastic syndromes (MDS) defined with an IPSS-R risk category of high or very high risk in combination with hypomethylating agents. NOVARTIS INVESTIGATIONAL ORAL THERAPY IPTACOPAN (LNP023 Paroxysmal nocturnal hemoglobinuria (PNH) is a rare and life-threatening blood disorder, resulting in debilitating symptoms that can impact patients’ quality of life 1–3; C3 glomerulopathy (C3G) is a rare renal disease, affecting young patients with a poor prognosis and significant unmet need 4-5; With potential to be the first oral treatment for a range of complement-driven diseases HOMEPAGE | NOVARTIS BIOME The Novartis Biome was created as a bridge to help our partners become an extension of our own teams, working with us as easily and productively as possible to jointly innovate and co SUSTAINABILITY-LINKED BOND DOCUMENTS Sustainability-linked Bond Documents. Final Listing Prospectus (PDF 1.1 MB) Sustainability-linked bond presentation (PDF 0.7 MB) Second party opinion of Sustainalytics (PDF 0.4 MB) Second party opinion of the independent Access to Medicine Foundation (ATMF) (PDF 0.2 MB) Limited assurance report of external verifier (PDF 0.1 MB) Twitter

Tweet.

NOVARTIS ENTRESTO® INDICATED FOR TREATMENT OF HYPERTENSION This investor update contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,”

“may,” “could

VP, GLOBAL HEAD OMNICHANNEL CUSTOMER ENGAGEMENT EEO Statement The Novartis Group of Companies are Equal Opportunity Employers and take pride in maintaining a diverse environment. We do not discriminate in recruitment, hiring, training, promotion or other employment practices for reasons of race, color, religion, gender, national origin, age, sexual orientation, gender identity or expression, marital or veteran status, disability, or any NOVARTISCAREERSINVESTORSOUR COMPANYOUR FOCUSOUR IMPACTOUR SCIENCE Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients

worldwide.

NOVARTIS ANNOUNCES IPTACOPAN MET PHASE II STUDY PRIMARY Phase II primary endpoint results for investigational iptacopan in IgAN demonstrated effective and clinically meaningful reduction of proteinuria 1 – a key risk predictor in kidney disease progression 2; Iptacopan also showed a trend toward stabilization of kidney function 1; Phase III clinical trial APPLAUSE is underway; There are no currently approved treatments for IgAN – a rare and NOVARTIS ANNOUNCES TABRECTA® FIRST PUBLISHED OVERALL Tabrecta ® (capmatinib) showed a median overall survival (OS) of 20.8 months in treatment-naïve patients and 13.6 months in previously-treated patients in first published mature data 1,2; Tabrecta achieved 65.6% overall response rate (ORR) in first-line and 51.6% in second-line settings in new expansion cohort analysis of additional patients 1,2; Patient-reported outcomes on quality-of-life NOVARTIS ANNOUNCES POSITIVE RESULT OF PHASE III STUDY WITH Phase III VISION study with 177 Lu-PSMA-617 met both primary endpoints, significantly improving overall survival (OS) and radiographic progression-free survival (rPFS) in patients with PSMA-positive metastatic castration-resistant prostate cancer 1; VISION trial findings to be presented at upcoming medical meeting, with regulatory submissions in the US and EU anticipated in 2021 NOVARTIS LIGELIZUMAB (QGE031) RECEIVES FDA BREAKTHROUGH Ligelizumab is the first treatment to receive FDA Breakthrough Therapy designation in chronic spontaneous urticaria (CSU) in patients with an inadequate response to H1-antihistamines 1; Currently there are limited approved therapies for patients NOVARTIS REPORTS CLINICALLY RELEVANT IMPROVEMENT IN MEDIAN At final analysis, study showed clinically relevant improvement in median overall survival with a difference of 11.7 months between arms (Hazard ratio (HR): 0.84 with 95% CI: (0.60, 1.17) (p=0.30, two-sided)) 1 ; No new safety signals emerged in long-term follow-up with median of 6.3 years; safety profile consistent with previously

reported results 1

NOVARTIS PHASE III BEOVU® DATA SHOW POTENTIAL FOR FLUID In KESTREL and KITE, Beovu (brolucizumab) 6 mg met the primary endpoints of non-inferiority in change in best corrected visual acuity from baseline versus aflibercept 2 mg at year one in diabetic macular edema (DME) patients 1; More patients treated with Beovu 6 mg experienced fluid (IRF/SRF) resolution at week 32 and week 52 versus aflibercept; fluid is a key marker of disease NOVARTIS TO UNVEIL NEW DATA AT ASCO AND EHA FROM ITS Overall survival and radiographic PFS from phase III study of investigational radioligand therapy 177 Lu-PSMA-617 VISION trial of patients with metastatic castration-resistant prostate cancer to be presented at ASCO plenary; New Kisqali (ribociclib)* overall survival data from extended follow-up of MONALEESA-3 trial in patients with postmenopausal HR+/HER2- advanced or metastatic breast cancer STUDY OF JDQ443 IN PATIENTS WITH ADVANCED SOLID TUMORS Study Description. This is a phase Ib/II open label study. The escalation part will characterize the safety and tolerability of JDQ443 single agent and JDQ443 in combination with the other study treatments (TNO155 and spartalizumab) in advanced solid tumor patients. After the determination of the maximum tolerated dose / recommended dose for a

BASE E12 - NOVARTIS

Metis. If you are using a basic mobile phone then click one of the below links to download the application. For MobileE12.jad. For

MobileE12MIDP1.jad

NOVARTISCAREERSINVESTORSOUR COMPANYOUR FOCUSOUR IMPACTOUR SCIENCE Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients

worldwide.

NOVARTIS ANNOUNCES IPTACOPAN MET PHASE II STUDY PRIMARY Phase II primary endpoint results for investigational iptacopan in IgAN demonstrated effective and clinically meaningful reduction of proteinuria 1 – a key risk predictor in kidney disease progression 2; Iptacopan also showed a trend toward stabilization of kidney function 1; Phase III clinical trial APPLAUSE is underway; There are no currently approved treatments for IgAN – a rare and NOVARTIS ANNOUNCES TABRECTA® FIRST PUBLISHED OVERALL Tabrecta ® (capmatinib) showed a median overall survival (OS) of 20.8 months in treatment-naïve patients and 13.6 months in previously-treated patients in first published mature data 1,2; Tabrecta achieved 65.6% overall response rate (ORR) in first-line and 51.6% in second-line settings in new expansion cohort analysis of additional patients 1,2; Patient-reported outcomes on quality-of-life NOVARTIS ANNOUNCES POSITIVE RESULT OF PHASE III STUDY WITH Phase III VISION study with 177 Lu-PSMA-617 met both primary endpoints, significantly improving overall survival (OS) and radiographic progression-free survival (rPFS) in patients with PSMA-positive metastatic castration-resistant prostate cancer 1; VISION trial findings to be presented at upcoming medical meeting, with regulatory submissions in the US and EU anticipated in 2021 NOVARTIS LIGELIZUMAB (QGE031) RECEIVES FDA BREAKTHROUGH Ligelizumab is the first treatment to receive FDA Breakthrough Therapy designation in chronic spontaneous urticaria (CSU) in patients with an inadequate response to H1-antihistamines 1; Currently there are limited approved therapies for patients NOVARTIS REPORTS CLINICALLY RELEVANT IMPROVEMENT IN MEDIAN At final analysis, study showed clinically relevant improvement in median overall survival with a difference of 11.7 months between arms (Hazard ratio (HR): 0.84 with 95% CI: (0.60, 1.17) (p=0.30, two-sided)) 1 ; No new safety signals emerged in long-term follow-up with median of 6.3 years; safety profile consistent with previously

reported results 1

NOVARTIS PHASE III BEOVU® DATA SHOW POTENTIAL FOR FLUID In KESTREL and KITE, Beovu (brolucizumab) 6 mg met the primary endpoints of non-inferiority in change in best corrected visual acuity from baseline versus aflibercept 2 mg at year one in diabetic macular edema (DME) patients 1; More patients treated with Beovu 6 mg experienced fluid (IRF/SRF) resolution at week 32 and week 52 versus aflibercept; fluid is a key marker of disease NOVARTIS TO UNVEIL NEW DATA AT ASCO AND EHA FROM ITS Overall survival and radiographic PFS from phase III study of investigational radioligand therapy 177 Lu-PSMA-617 VISION trial of patients with metastatic castration-resistant prostate cancer to be presented at ASCO plenary; New Kisqali (ribociclib)* overall survival data from extended follow-up of MONALEESA-3 trial in patients with postmenopausal HR+/HER2- advanced or metastatic breast cancer STUDY OF JDQ443 IN PATIENTS WITH ADVANCED SOLID TUMORS Study Description. This is a phase Ib/II open label study. The escalation part will characterize the safety and tolerability of JDQ443 single agent and JDQ443 in combination with the other study treatments (TNO155 and spartalizumab) in advanced solid tumor patients. After the determination of the maximum tolerated dose / recommended dose for a

BASE E12 - NOVARTIS

Metis. If you are using a basic mobile phone then click one of the below links to download the application. For MobileE12.jad. For

MobileE12MIDP1.jad

NOVARTIS GLOBAL PIPELINE Novartis Global Pipeline. Benefitting from our continued focus on innovation, Novartis has one of the industry’s most competitive pipelines with more than 200 projects in clinical development. Many of these projects, which include new molecular entities as well as additional indications and different formulations for marketed

products, are

CAREER SEARCH

Novartis Gene Therapies, GTx (formerly AveXis) has had one focus; to bring change to those devastated by rare and life-threatening genetic neurological diseases. Gene Therapy roles can be found across Novartis and within the dedicated GTx team. For gene therapy roles in Novartis,

free text search

NOVARTIS PROVIDES UPDATE ON USE AND SAFETY OF BEOVU® IN March 02, 2020. As of March 2, 2020, more than 57,000 Beovu® (brolucizumab) vials for injection have been shipped to prescribing physicians in the US 1.To date, the safety data continue to support a favorable benefit-risk profile for Beovu 2,3.. Beovu is approved for the treatment of wet age-related macular degeneration (wet AMD) by the US Food & Drug Administration (FDA), the European HOMEPAGE | NOVARTIS BIOME The Novartis Biome was created as a bridge to help our partners become an extension of our own teams, working with us as easily and productively as possible to jointly innovate and co NOVARTIS REPORTS ONE YEAR RESULTS OF PHASE III MERLIN Beovu (brolucizumab) met MERLIN’s primary endpoint of non-inferiority in change in best corrected visual acuity from baseline and superiority on anatomical secondary endpoints at year one versus aflibercept when given every four weeks following the loading phase 1; In this study evaluating every four week dosing, Beovu was associated with higher rates of IOI including retinal vasculitis and NOVARTIS ANNOUNCES EU APPROVAL OF MAYZENT® (SIPONIMOD) FOR Mayzent ® (siponimod) is the first and only oral treatment specifically indicated for patients with secondary progressive multiple sclerosis (SPMS) with active disease in Europe 1; Mayzent addresses an unmet need for SPMS patients with active disease who, until now, did not have an oral treatment that has been shown to be effective in delaying progression in this patient population NOVARTIS ANNOUNCES COMPLETION OF TRANSACTIONS WITH GSK The transactions were announced in April 2014 as part of the Novartis global portfolio transformation. "The completion of the GSK transactions focuses Novartis, and further establishes our leading positions in key growing business segments," said Joseph Jimenez, CEO of Novartis. "We expect this evolution of our strategy to improve

margin

NOVARTIS POSITION ON POST-TRIAL ACCESS Novartis Corporate Affairs Public Affairs Policy Novartis Position on Post-Trial Access1. The mission of Novartis is to discover new ways to improve and extend people’s KESIMPTA AND VACCINES KESIMPTA AND VACCINES Vaccine and vaccine-related information from the KESIMPTA Prescribing Information and pivotal trials INDICATION KESIMPTA is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome,

BASE E12 - NOVARTIS

Metis. If you are using a basic mobile phone then click one of the below links to download the application. For MobileE12.jad. For

MobileE12MIDP1.jad

NOVARTISCAREERSINVESTORSOUR COMPANYOUR FOCUSOUR IMPACTOUR SCIENCE Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients

worldwide.

NOVARTIS ANNOUNCES POSITIVE RESULT OF PHASE III STUDY WITH Phase III VISION study with 177 Lu-PSMA-617 met both primary endpoints, significantly improving overall survival (OS) and radiographic progression-free survival (rPFS) in patients with PSMA-positive metastatic castration-resistant prostate cancer 1; VISION trial findings to be presented at upcoming medical meeting, with regulatory submissions in the US and EU anticipated in 2021 NOVARTIS REPORTS ONE YEAR RESULTS OF PHASE III MERLIN Beovu (brolucizumab) met MERLIN’s primary endpoint of non-inferiority in change in best corrected visual acuity from baseline and superiority on anatomical secondary endpoints at year one versus aflibercept when given every four weeks following the loading phase 1; In this study evaluating every four week dosing, Beovu was associated with higher rates of IOI including retinal vasculitis and NOVARTIS TO UNVEIL NEW DATA AT ASCO AND EHA FROM ITS Overall survival and radiographic PFS from phase III study of investigational radioligand therapy 177 Lu-PSMA-617 VISION trial of patients with metastatic castration-resistant prostate cancer to be presented at ASCO plenary; New Kisqali (ribociclib)* overall survival data from extended follow-up of MONALEESA-3 trial in patients with postmenopausal HR+/HER2- advanced or metastatic breast cancer SUSTAINABILITY-LINKED BOND DOCUMENTS Sustainability-linked Bond Documents. Final Listing Prospectus (PDF 1.1 MB) Sustainability-linked bond presentation (PDF 0.7 MB) Second party opinion of Sustainalytics (PDF 0.4 MB) Second party opinion of the independent Access to Medicine Foundation (ATMF) (PDF 0.2 MB) Limited assurance report of external verifier (PDF 0.1 MB) Twitter

Tweet.

NOVARTIS ANNOUNCES EU APPROVAL OF MAYZENT® (SIPONIMOD) FOR Mayzent ® (siponimod) is the first and only oral treatment specifically indicated for patients with secondary progressive multiple sclerosis (SPMS) with active disease in Europe 1; Mayzent addresses an unmet need for SPMS patients with active disease who, until now, did not have an oral treatment that has been shown to be effective in delaying progression in this patient population STUDY OF JDQ443 IN PATIENTS WITH ADVANCED SOLID TUMORS Study Description. This is a phase Ib/II open label study. The escalation part will characterize the safety and tolerability of JDQ443 single agent and JDQ443 in combination with the other study treatments (TNO155 and spartalizumab) in advanced solid tumor patients. After the determination of the maximum tolerated dose / recommended dose for a PROFESSIONAL PRACTICES POLICY (P3) Novartis Global Policy Professional Practices Policy (P3) Novartis Global Policy March 1st, 2018 Version GIC 102.V1.EN KESIMPTA AND VACCINES KESIMPTA AND VACCINES Vaccine and vaccine-related information from the KESIMPTA Prescribing Information and pivotal trials INDICATION KESIMPTA is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome,

BASE E12 - NOVARTIS

Metis. If you are using a basic mobile phone then click one of the below links to download the application. For MobileE12.jad. For

MobileE12MIDP1.jad

NOVARTISCAREERSINVESTORSOUR COMPANYOUR FOCUSOUR IMPACTOUR SCIENCE Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients

worldwide.

NOVARTIS ANNOUNCES POSITIVE RESULT OF PHASE III STUDY WITH Phase III VISION study with 177 Lu-PSMA-617 met both primary endpoints, significantly improving overall survival (OS) and radiographic progression-free survival (rPFS) in patients with PSMA-positive metastatic castration-resistant prostate cancer 1; VISION trial findings to be presented at upcoming medical meeting, with regulatory submissions in the US and EU anticipated in 2021 NOVARTIS REPORTS ONE YEAR RESULTS OF PHASE III MERLIN Beovu (brolucizumab) met MERLIN’s primary endpoint of non-inferiority in change in best corrected visual acuity from baseline and superiority on anatomical secondary endpoints at year one versus aflibercept when given every four weeks following the loading phase 1; In this study evaluating every four week dosing, Beovu was associated with higher rates of IOI including retinal vasculitis and NOVARTIS TO UNVEIL NEW DATA AT ASCO AND EHA FROM ITS Overall survival and radiographic PFS from phase III study of investigational radioligand therapy 177 Lu-PSMA-617 VISION trial of patients with metastatic castration-resistant prostate cancer to be presented at ASCO plenary; New Kisqali (ribociclib)* overall survival data from extended follow-up of MONALEESA-3 trial in patients with postmenopausal HR+/HER2- advanced or metastatic breast cancer SUSTAINABILITY-LINKED BOND DOCUMENTS Sustainability-linked Bond Documents. Final Listing Prospectus (PDF 1.1 MB) Sustainability-linked bond presentation (PDF 0.7 MB) Second party opinion of Sustainalytics (PDF 0.4 MB) Second party opinion of the independent Access to Medicine Foundation (ATMF) (PDF 0.2 MB) Limited assurance report of external verifier (PDF 0.1 MB) Twitter

Tweet.

NOVARTIS ANNOUNCES EU APPROVAL OF MAYZENT® (SIPONIMOD) FOR Mayzent ® (siponimod) is the first and only oral treatment specifically indicated for patients with secondary progressive multiple sclerosis (SPMS) with active disease in Europe 1; Mayzent addresses an unmet need for SPMS patients with active disease who, until now, did not have an oral treatment that has been shown to be effective in delaying progression in this patient population STUDY OF JDQ443 IN PATIENTS WITH ADVANCED SOLID TUMORS Study Description. This is a phase Ib/II open label study. The escalation part will characterize the safety and tolerability of JDQ443 single agent and JDQ443 in combination with the other study treatments (TNO155 and spartalizumab) in advanced solid tumor patients. After the determination of the maximum tolerated dose / recommended dose for a PROFESSIONAL PRACTICES POLICY (P3) Novartis Global Policy Professional Practices Policy (P3) Novartis Global Policy March 1st, 2018 Version GIC 102.V1.EN KESIMPTA AND VACCINES KESIMPTA AND VACCINES Vaccine and vaccine-related information from the KESIMPTA Prescribing Information and pivotal trials INDICATION KESIMPTA is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome,

BASE E12 - NOVARTIS

Metis. If you are using a basic mobile phone then click one of the below links to download the application. For MobileE12.jad. For

MobileE12MIDP1.jad

NOVARTIS ANNUAL REPORT 2020 This report, filed with the SIX Swiss Exchange in Switzerland, provides a comprehensive overview of Novartis, including our company structure, corporate governance and compensation practices. It also discloses our operating and financial results, accompanied by audited annual financial statements.

CAREER SEARCH

Novartis Gene Therapies, GTx (formerly AveXis) has had one focus; to bring change to those devastated by rare and life-threatening genetic neurological diseases. Gene Therapy roles can be found across Novartis and within the dedicated GTx team. For gene therapy roles in Novartis,

free text search

NOVARTIS GLOBAL PIPELINE Novartis Global Pipeline. Benefitting from our continued focus on innovation, Novartis has one of the industry’s most competitive pipelines with more than 200 projects in clinical development. Many of these projects, which include new molecular entities as well as additional indications and different formulations for marketed

products, are

NOVARTIS CARDIOVASCULAR UPDATE Entresto® (titrate to 200 mg bid; dose adjustment permitted) Ramipril (titrate to 5 mg bid; dose adjustment permitted) Screen Randomize between 12hrs up to 7 days after an AMI Wk1 2 Month 1 Month 2 Month 4 Month 8 Month 12 Month 16 Month 20

NOVARTIS PARTNERING

Our commitment is to help accelerate the discovery and development of transformative medicines. It is imperative that we remain open to partnering on, or acquiring, transformational ideas being developed outside our company. Deal making and partnering play a key role in our strategy and are critical to our long-term success. NOVARTIS LIGELIZUMAB (QGE031) RECEIVES FDA BREAKTHROUGH Ligelizumab is the first treatment to receive FDA Breakthrough Therapy designation in chronic spontaneous urticaria (CSU) in patients with an inadequate response to H1-antihistamines 1; Currently there are limited approved therapies for patients NOVARTIS ANNOUNCES EU APPROVAL OF MAYZENT® (SIPONIMOD) FOR Mayzent ® (siponimod) is the first and only oral treatment specifically indicated for patients with secondary progressive multiple sclerosis (SPMS) with active disease in Europe 1; Mayzent addresses an unmet need for SPMS patients with active disease who, until now, did not have an oral treatment that has been shown to be effective in delaying progression in this patient population THE DATA42 PROGRAM SHOWS NOVARTIS’ INTENT TO GO BIG ON The data42 program shows Novartis’ intent to go big on data and digital. Novartis is betting on both human inquisitiveness and computer expertise to harness the wealth of its digital research and development platform, data42. Although artificial intelligence has been around for decades, recent developments in the realm of deep

learning have

NOVARTIS ANNOUNCES COMPLETION OF TRANSACTIONS WITH GSK The transactions were announced in April 2014 as part of the Novartis global portfolio transformation. "The completion of the GSK transactions focuses Novartis, and further establishes our leading positions in key growing business segments," said Joseph Jimenez, CEO of Novartis. "We expect this evolution of our strategy to improve

margin

PROFESSIONAL PRACTICES POLICY (P3) Novartis Global Policy Professional Practices Policy (P3) Novartis Global Policy March 1st, 2018 Version GIC 102.V1.EN NOVARTISCAREERSINVESTORSOUR COMPANYOUR FOCUSOUR IMPACTOUR SCIENCE Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients

worldwide.

CAREERS | NOVARTIS

International Careers. Novartis is committed to supporting our personal growth. Helping us and our families to relocate for an international career or for a development opportunity are just two ways in which we are supported. International Careers. International

Careers.

NOVARTIS ANNUAL REPORT 2020 This report, filed with the SIX Swiss Exchange in Switzerland, provides a comprehensive overview of Novartis, including our company structure, corporate governance and compensation practices. It also discloses our operating and financial results, accompanied by audited annual financial statements. NOVARTIS REPORTS ONE YEAR RESULTS OF PHASE III MERLIN Beovu (brolucizumab) met MERLIN’s primary endpoint of non-inferiority in change in best corrected visual acuity from baseline and superiority on anatomical secondary endpoints at year one versus aflibercept when given every four weeks following the loading phase 1; In this study evaluating every four week dosing, Beovu was associated with higher rates of IOI including retinal vasculitis and NOVARTIS PROVIDES UPDATE ON USE AND SAFETY OF BEOVU® INLIST OF NOVARTIS DRUGSNOVARTIS OPHTHALMIC DRUGSNOVARTIS PHARMACEUTICAL PRODUCTSNOVARTIS PHARMACEUTICALS March 02, 2020. As of March 2, 2020, more than 57,000 Beovu® (brolucizumab) vials for injection have been shipped to prescribing physicians in the US 1.To date, the safety data continue to support a favorable benefit-risk profile for Beovu 2,3.. Beovu is approved for the treatment of wet age-related macular degeneration (wet AMD) by the US Food & Drug Administration (FDA), the European

OPHTHALMOLOGY

Learn how innovative ophthalmology research at Novartis is producing therapies that treat retina diseases, glaucoma, presbyopia, dry eye, ocular surface diseases, other external eye diseases and inherited

retinal diseases.

NOVARTIS ANNOUNCES POSITIVE RESULT OF PHASE III STUDY WITH Phase III VISION study with 177 Lu-PSMA-617 met both primary endpoints, significantly improving overall survival (OS) and radiographic progression-free survival (rPFS) in patients with PSMA-positive metastatic castration-resistant prostate cancer 1; VISION trial findings to be presented at upcoming medical meeting, with regulatory submissions in the US and EU anticipated in 2021 SUSTAINABILITY-LINKED BOND DOCUMENTS Sustainability-linked Bond Documents. Final Listing Prospectus (PDF 1.1 MB) Sustainability-linked bond presentation (PDF 0.7 MB) Second party opinion of Sustainalytics (PDF 0.4 MB) Second party opinion of the independent Access to Medicine Foundation (ATMF) (PDF 0.2 MB) Limited assurance report of external verifier (PDF 0.1 MB) Twitter

Tweet.

THE DATA42 PROGRAM SHOWS NOVARTIS’ INTENT TO GO BIG ON The data42 program shows Novartis’ intent to go big on data and digital. Novartis is betting on both human inquisitiveness and computer expertise to harness the wealth of its digital research and development platform, data42. Although artificial intelligence has been around for decades, recent developments in the realm of deep

learning have

PROFESSIONAL PRACTICES POLICY (P3) Novartis Global Policy Professional Practices Policy (P3) Novartis Global Policy March 1st, 2018 Version GIC 102.V1.EN NOVARTISCAREERSINVESTORSOUR COMPANYOUR FOCUSOUR IMPACTOUR SCIENCE Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients

worldwide.

CAREERS | NOVARTIS

International Careers. Novartis is committed to supporting our personal growth. Helping us and our families to relocate for an international career or for a development opportunity are just two ways in which we are supported. International Careers. International

Careers.

NOVARTIS ANNUAL REPORT 2020 This report, filed with the SIX Swiss Exchange in Switzerland, provides a comprehensive overview of Novartis, including our company structure, corporate governance and compensation practices. It also discloses our operating and financial results, accompanied by audited annual financial statements. NOVARTIS REPORTS ONE YEAR RESULTS OF PHASE III MERLIN Beovu (brolucizumab) met MERLIN’s primary endpoint of non-inferiority in change in best corrected visual acuity from baseline and superiority on anatomical secondary endpoints at year one versus aflibercept when given every four weeks following the loading phase 1; In this study evaluating every four week dosing, Beovu was associated with higher rates of IOI including retinal vasculitis and NOVARTIS PROVIDES UPDATE ON USE AND SAFETY OF BEOVU® INLIST OF NOVARTIS DRUGSNOVARTIS OPHTHALMIC DRUGSNOVARTIS PHARMACEUTICAL PRODUCTSNOVARTIS PHARMACEUTICALS March 02, 2020. As of March 2, 2020, more than 57,000 Beovu® (brolucizumab) vials for injection have been shipped to prescribing physicians in the US 1.To date, the safety data continue to support a favorable benefit-risk profile for Beovu 2,3.. Beovu is approved for the treatment of wet age-related macular degeneration (wet AMD) by the US Food & Drug Administration (FDA), the European

OPHTHALMOLOGY

Learn how innovative ophthalmology research at Novartis is producing therapies that treat retina diseases, glaucoma, presbyopia, dry eye, ocular surface diseases, other external eye diseases and inherited

retinal diseases.

NOVARTIS ANNOUNCES POSITIVE RESULT OF PHASE III STUDY WITH Phase III VISION study with 177 Lu-PSMA-617 met both primary endpoints, significantly improving overall survival (OS) and radiographic progression-free survival (rPFS) in patients with PSMA-positive metastatic castration-resistant prostate cancer 1; VISION trial findings to be presented at upcoming medical meeting, with regulatory submissions in the US and EU anticipated in 2021 SUSTAINABILITY-LINKED BOND DOCUMENTS Sustainability-linked Bond Documents. Final Listing Prospectus (PDF 1.1 MB) Sustainability-linked bond presentation (PDF 0.7 MB) Second party opinion of Sustainalytics (PDF 0.4 MB) Second party opinion of the independent Access to Medicine Foundation (ATMF) (PDF 0.2 MB) Limited assurance report of external verifier (PDF 0.1 MB) Twitter

Tweet.

THE DATA42 PROGRAM SHOWS NOVARTIS’ INTENT TO GO BIG ON The data42 program shows Novartis’ intent to go big on data and digital. Novartis is betting on both human inquisitiveness and computer expertise to harness the wealth of its digital research and development platform, data42. Although artificial intelligence has been around for decades, recent developments in the realm of deep

learning have

PROFESSIONAL PRACTICES POLICY (P3) Novartis Global Policy Professional Practices Policy (P3) Novartis Global Policy March 1st, 2018 Version GIC 102.V1.EN

NOVARTIS

Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients

worldwide.

NOVARTIS PROVIDES UPDATE ON USE AND SAFETY OF BEOVU® IN March 02, 2020. As of March 2, 2020, more than 57,000 Beovu® (brolucizumab) vials for injection have been shipped to prescribing physicians in the US 1.To date, the safety data continue to support a favorable benefit-risk profile for Beovu 2,3.. Beovu is approved for the treatment of wet age-related macular degeneration (wet AMD) by the US Food & Drug Administration (FDA), the European

OPHTHALMOLOGY

Learn how innovative ophthalmology research at Novartis is producing therapies that treat retina diseases, glaucoma, presbyopia, dry eye, ocular surface diseases, other external eye diseases and inherited

retinal diseases.

IMMUNOLOGY & DERMATOLOGY Novartis is a global leader in immunology and dermatology. We are transforming the lives of people living with immunologic diseases, focusing on specialty dermatology, rheumatology, autoinflammatory, transplant, and specialty liver diseases where there remain high unmet

medical needs.

NOVARTIS ANNOUNCES POSITIVE RESULT OF PHASE III STUDY WITH Phase III VISION study with 177 Lu-PSMA-617 met both primary endpoints, significantly improving overall survival (OS) and radiographic progression-free survival (rPFS) in patients with PSMA-positive metastatic castration-resistant prostate cancer 1; VISION trial findings to be presented at upcoming medical meeting, with regulatory submissions in the US and EU anticipated in 2021 INVESTIGATOR-INITIATED TRIALS / STUDIES Novartis is committed to supporting Investigator Initiated Trials (IITs) as a part of the drug discovery and development process. Scientific research that is produced by qualified third-party investigators is key to complementing Novartis-sponsored research to help better understand the benefit/risk profile of our therapies as well as explore new opportunities to address unmet HOMEPAGE | NOVARTIS BIOME The Novartis Biome was created as a bridge to help our partners become an extension of our own teams, working with us as easily and productively as possible to jointly innovate and co EXECUTIVE DIRECTOR, GLOBAL NEW PRODUCTS- OPTHALMOLOGY 4.3 million patients were served by our Ophthalmology group in 2018. We are Novartis. Join us and help reimagine medicine The Executive New Products Director is a Global role serving as a core member of one or more Global Program Teams (GPT) for Novartis molecules in clinical development. He or she SECURITY OPERATIONS EXPERT 25! Information Security Tools! Would you like to have hands-on experience in these industry leading security products? Join our awesome Security Operations Automation Team! In this role you will contribute to the day-to-day management of a set of systems, tools or applications, ensuring their

BASE E12 - NOVARTIS

Metis. If you are using a basic mobile phone then click one of the below links to download the application. For MobileE12.jad. For

MobileE12MIDP1.jad

NOVARTISCAREERSINVESTORSOUR COMPANYOUR FOCUSOUR IMPACTOUR SCIENCE Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients

worldwide.

CAREERS | NOVARTIS

International Careers. Novartis is committed to supporting our personal growth. Helping us and our families to relocate for an international career or for a development opportunity are just two ways in which we are supported. International Careers. International

Careers.

NOVARTIS ANNUAL REPORT 2020 This report, filed with the SIX Swiss Exchange in Switzerland, provides a comprehensive overview of Novartis, including our company structure, corporate governance and compensation practices. It also discloses our operating and financial results, accompanied by audited annual financial statements. NOVARTIS REPORTS ONE YEAR RESULTS OF PHASE III MERLIN Beovu (brolucizumab) met MERLIN’s primary endpoint of non-inferiority in change in best corrected visual acuity from baseline and superiority on anatomical secondary endpoints at year one versus aflibercept when given every four weeks following the loading phase 1; In this study evaluating every four week dosing, Beovu was associated with higher rates of IOI including retinal vasculitis and NOVARTIS PROVIDES UPDATE ON USE AND SAFETY OF BEOVU® INLIST OF NOVARTIS DRUGSNOVARTIS OPHTHALMIC DRUGSNOVARTIS PHARMACEUTICAL PRODUCTSNOVARTIS PHARMACEUTICALS March 02, 2020. As of March 2, 2020, more than 57,000 Beovu® (brolucizumab) vials for injection have been shipped to prescribing physicians in the US 1.To date, the safety data continue to support a favorable benefit-risk profile for Beovu 2,3.. Beovu is approved for the treatment of wet age-related macular degeneration (wet AMD) by the US Food & Drug Administration (FDA), the European

OPHTHALMOLOGY

Learn how innovative ophthalmology research at Novartis is producing therapies that treat retina diseases, glaucoma, presbyopia, dry eye, ocular surface diseases, other external eye diseases and inherited

retinal diseases.

NOVARTIS ANNOUNCES POSITIVE RESULT OF PHASE III STUDY WITH Phase III VISION study with 177 Lu-PSMA-617 met both primary endpoints, significantly improving overall survival (OS) and radiographic progression-free survival (rPFS) in patients with PSMA-positive metastatic castration-resistant prostate cancer 1; VISION trial findings to be presented at upcoming medical meeting, with regulatory submissions in the US and EU anticipated in 2021 SUSTAINABILITY-LINKED BOND DOCUMENTS Sustainability-linked Bond Documents. Final Listing Prospectus (PDF 1.1 MB) Sustainability-linked bond presentation (PDF 0.7 MB) Second party opinion of Sustainalytics (PDF 0.4 MB) Second party opinion of the independent Access to Medicine Foundation (ATMF) (PDF 0.2 MB) Limited assurance report of external verifier (PDF 0.1 MB) Twitter

Tweet.

THE DATA42 PROGRAM SHOWS NOVARTIS’ INTENT TO GO BIG ON The data42 program shows Novartis’ intent to go big on data and digital. Novartis is betting on both human inquisitiveness and computer expertise to harness the wealth of its digital research and development platform, data42. Although artificial intelligence has been around for decades, recent developments in the realm of deep

learning have

PROFESSIONAL PRACTICES POLICY (P3) Novartis Global Policy Professional Practices Policy (P3) Novartis Global Policy March 1st, 2018 Version GIC 102.V1.EN NOVARTISCAREERSINVESTORSOUR COMPANYOUR FOCUSOUR IMPACTOUR SCIENCE Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients

worldwide.

CAREERS | NOVARTIS

International Careers. Novartis is committed to supporting our personal growth. Helping us and our families to relocate for an international career or for a development opportunity are just two ways in which we are supported. International Careers. International

Careers.

NOVARTIS ANNUAL REPORT 2020 This report, filed with the SIX Swiss Exchange in Switzerland, provides a comprehensive overview of Novartis, including our company structure, corporate governance and compensation practices. It also discloses our operating and financial results, accompanied by audited annual financial statements. NOVARTIS REPORTS ONE YEAR RESULTS OF PHASE III MERLIN Beovu (brolucizumab) met MERLIN’s primary endpoint of non-inferiority in change in best corrected visual acuity from baseline and superiority on anatomical secondary endpoints at year one versus aflibercept when given every four weeks following the loading phase 1; In this study evaluating every four week dosing, Beovu was associated with higher rates of IOI including retinal vasculitis and NOVARTIS PROVIDES UPDATE ON USE AND SAFETY OF BEOVU® INLIST OF NOVARTIS DRUGSNOVARTIS OPHTHALMIC DRUGSNOVARTIS PHARMACEUTICAL PRODUCTSNOVARTIS PHARMACEUTICALS March 02, 2020. As of March 2, 2020, more than 57,000 Beovu® (brolucizumab) vials for injection have been shipped to prescribing physicians in the US 1.To date, the safety data continue to support a favorable benefit-risk profile for Beovu 2,3.. Beovu is approved for the treatment of wet age-related macular degeneration (wet AMD) by the US Food & Drug Administration (FDA), the European

OPHTHALMOLOGY

Learn how innovative ophthalmology research at Novartis is producing therapies that treat retina diseases, glaucoma, presbyopia, dry eye, ocular surface diseases, other external eye diseases and inherited

retinal diseases.

NOVARTIS ANNOUNCES POSITIVE RESULT OF PHASE III STUDY WITH Phase III VISION study with 177 Lu-PSMA-617 met both primary endpoints, significantly improving overall survival (OS) and radiographic progression-free survival (rPFS) in patients with PSMA-positive metastatic castration-resistant prostate cancer 1; VISION trial findings to be presented at upcoming medical meeting, with regulatory submissions in the US and EU anticipated in 2021 SUSTAINABILITY-LINKED BOND DOCUMENTS Sustainability-linked Bond Documents. Final Listing Prospectus (PDF 1.1 MB) Sustainability-linked bond presentation (PDF 0.7 MB) Second party opinion of Sustainalytics (PDF 0.4 MB) Second party opinion of the independent Access to Medicine Foundation (ATMF) (PDF 0.2 MB) Limited assurance report of external verifier (PDF 0.1 MB) Twitter

Tweet.

THE DATA42 PROGRAM SHOWS NOVARTIS’ INTENT TO GO BIG ON The data42 program shows Novartis’ intent to go big on data and digital. Novartis is betting on both human inquisitiveness and computer expertise to harness the wealth of its digital research and development platform, data42. Although artificial intelligence has been around for decades, recent developments in the realm of deep

learning have

PROFESSIONAL PRACTICES POLICY (P3) Novartis Global Policy Professional Practices Policy (P3) Novartis Global Policy March 1st, 2018 Version GIC 102.V1.EN

NOVARTIS

Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients

worldwide.

NOVARTIS PROVIDES UPDATE ON USE AND SAFETY OF BEOVU® IN March 02, 2020. As of March 2, 2020, more than 57,000 Beovu® (brolucizumab) vials for injection have been shipped to prescribing physicians in the US 1.To date, the safety data continue to support a favorable benefit-risk profile for Beovu 2,3.. Beovu is approved for the treatment of wet age-related macular degeneration (wet AMD) by the US Food & Drug Administration (FDA), the European

OPHTHALMOLOGY

Learn how innovative ophthalmology research at Novartis is producing therapies that treat retina diseases, glaucoma, presbyopia, dry eye, ocular surface diseases, other external eye diseases and inherited

retinal diseases.

IMMUNOLOGY & DERMATOLOGY Novartis is a global leader in immunology and dermatology. We are transforming the lives of people living with immunologic diseases, focusing on specialty dermatology, rheumatology, autoinflammatory, transplant, and specialty liver diseases where there remain high unmet

medical needs.

NOVARTIS ANNOUNCES POSITIVE RESULT OF PHASE III STUDY WITH Phase III VISION study with 177 Lu-PSMA-617 met both primary endpoints, significantly improving overall survival (OS) and radiographic progression-free survival (rPFS) in patients with PSMA-positive metastatic castration-resistant prostate cancer 1; VISION trial findings to be presented at upcoming medical meeting, with regulatory submissions in the US and EU anticipated in 2021 INVESTIGATOR-INITIATED TRIALS / STUDIES Novartis is committed to supporting Investigator Initiated Trials (IITs) as a part of the drug discovery and development process. Scientific research that is produced by qualified third-party investigators is key to complementing Novartis-sponsored research to help better understand the benefit/risk profile of our therapies as well as explore new opportunities to address unmet HOMEPAGE | NOVARTIS BIOME The Novartis Biome was created as a bridge to help our partners become an extension of our own teams, working with us as easily and productively as possible to jointly innovate and co EXECUTIVE DIRECTOR, GLOBAL NEW PRODUCTS- OPTHALMOLOGY 4.3 million patients were served by our Ophthalmology group in 2018. We are Novartis. Join us and help reimagine medicine The Executive New Products Director is a Global role serving as a core member of one or more Global Program Teams (GPT) for Novartis molecules in clinical development. He or she SECURITY OPERATIONS EXPERT 25! Information Security Tools! Would you like to have hands-on experience in these industry leading security products? Join our awesome Security Operations Automation Team! In this role you will contribute to the day-to-day management of a set of systems, tools or applications, ensuring their

BASE E12 - NOVARTIS

Metis. If you are using a basic mobile phone then click one of the below links to download the application. For MobileE12.jad. For

MobileE12MIDP1.jad

NOVARTISCAREERSINVESTORSOUR COMPANYOUR FOCUSOUR IMPACTOUR SCIENCE Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients

worldwide.

CAREERS | NOVARTIS

International Careers. Novartis is committed to supporting our personal growth. Helping us and our families to relocate for an international career or for a development opportunity are just two ways in which we are supported. International Careers. International

Careers.

NOVARTIS ANNUAL REPORT 2020 This report, filed with the SIX Swiss Exchange in Switzerland, provides a comprehensive overview of Novartis, including our company structure, corporate governance and compensation practices. It also discloses our operating and financial results, accompanied by audited annual financial statements. NOVARTIS REPORTS ONE YEAR RESULTS OF PHASE III MERLIN Beovu (brolucizumab) met MERLIN’s primary endpoint of non-inferiority in change in best corrected visual acuity from baseline and superiority on anatomical secondary endpoints at year one versus aflibercept when given every four weeks following the loading phase 1; In this study evaluating every four week dosing, Beovu was associated with higher rates of IOI including retinal vasculitis and NOVARTIS PROVIDES UPDATE ON USE AND SAFETY OF BEOVU® INLIST OF NOVARTIS DRUGSNOVARTIS OPHTHALMIC DRUGSNOVARTIS PHARMACEUTICAL PRODUCTSNOVARTIS PHARMACEUTICALS March 02, 2020. As of March 2, 2020, more than 57,000 Beovu® (brolucizumab) vials for injection have been shipped to prescribing physicians in the US 1.To date, the safety data continue to support a favorable benefit-risk profile for Beovu 2,3.. Beovu is approved for the treatment of wet age-related macular degeneration (wet AMD) by the US Food & Drug Administration (FDA), the European

OPHTHALMOLOGY

Learn how innovative ophthalmology research at Novartis is producing therapies that treat retina diseases, glaucoma, presbyopia, dry eye, ocular surface diseases, other external eye diseases and inherited

retinal diseases.

NOVARTIS ANNOUNCES POSITIVE RESULT OF PHASE III STUDY WITH Phase III VISION study with 177 Lu-PSMA-617 met both primary endpoints, significantly improving overall survival (OS) and radiographic progression-free survival (rPFS) in patients with PSMA-positive metastatic castration-resistant prostate cancer 1; VISION trial findings to be presented at upcoming medical meeting, with regulatory submissions in the US and EU anticipated in 2021 SUSTAINABILITY-LINKED BOND DOCUMENTS Sustainability-linked Bond Documents. Final Listing Prospectus (PDF 1.1 MB) Sustainability-linked bond presentation (PDF 0.7 MB) Second party opinion of Sustainalytics (PDF 0.4 MB) Second party opinion of the independent Access to Medicine Foundation (ATMF) (PDF 0.2 MB) Limited assurance report of external verifier (PDF 0.1 MB) Twitter

Tweet.

THE DATA42 PROGRAM SHOWS NOVARTIS’ INTENT TO GO BIG ON The data42 program shows Novartis’ intent to go big on data and digital. Novartis is betting on both human inquisitiveness and computer expertise to harness the wealth of its digital research and development platform, data42. Although artificial intelligence has been around for decades, recent developments in the realm of deep

learning have

PROFESSIONAL PRACTICES POLICY (P3) Novartis Global Policy Professional Practices Policy (P3) Novartis Global Policy March 1st, 2018 Version GIC 102.V1.EN NOVARTISCAREERSINVESTORSOUR COMPANYOUR FOCUSOUR IMPACTOUR SCIENCE Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients

worldwide.

CAREERS | NOVARTIS

International Careers. Novartis is committed to supporting our personal growth. Helping us and our families to relocate for an international career or for a development opportunity are just two ways in which we are supported. International Careers. International

Careers.

NOVARTIS ANNUAL REPORT 2020 This report, filed with the SIX Swiss Exchange in Switzerland, provides a comprehensive overview of Novartis, including our company structure, corporate governance and compensation practices. It also discloses our operating and financial results, accompanied by audited annual financial statements. NOVARTIS REPORTS ONE YEAR RESULTS OF PHASE III MERLIN Beovu (brolucizumab) met MERLIN’s primary endpoint of non-inferiority in change in best corrected visual acuity from baseline and superiority on anatomical secondary endpoints at year one versus aflibercept when given every four weeks following the loading phase 1; In this study evaluating every four week dosing, Beovu was associated with higher rates of IOI including retinal vasculitis and NOVARTIS PROVIDES UPDATE ON USE AND SAFETY OF BEOVU® INLIST OF NOVARTIS DRUGSNOVARTIS OPHTHALMIC DRUGSNOVARTIS PHARMACEUTICAL PRODUCTSNOVARTIS PHARMACEUTICALS March 02, 2020. As of March 2, 2020, more than 57,000 Beovu® (brolucizumab) vials for injection have been shipped to prescribing physicians in the US 1.To date, the safety data continue to support a favorable benefit-risk profile for Beovu 2,3.. Beovu is approved for the treatment of wet age-related macular degeneration (wet AMD) by the US Food & Drug Administration (FDA), the European

OPHTHALMOLOGY

Learn how innovative ophthalmology research at Novartis is producing therapies that treat retina diseases, glaucoma, presbyopia, dry eye, ocular surface diseases, other external eye diseases and inherited

retinal diseases.

NOVARTIS ANNOUNCES POSITIVE RESULT OF PHASE III STUDY WITH Phase III VISION study with 177 Lu-PSMA-617 met both primary endpoints, significantly improving overall survival (OS) and radiographic progression-free survival (rPFS) in patients with PSMA-positive metastatic castration-resistant prostate cancer 1; VISION trial findings to be presented at upcoming medical meeting, with regulatory submissions in the US and EU anticipated in 2021 SUSTAINABILITY-LINKED BOND DOCUMENTS Sustainability-linked Bond Documents. Final Listing Prospectus (PDF 1.1 MB) Sustainability-linked bond presentation (PDF 0.7 MB) Second party opinion of Sustainalytics (PDF 0.4 MB) Second party opinion of the independent Access to Medicine Foundation (ATMF) (PDF 0.2 MB) Limited assurance report of external verifier (PDF 0.1 MB) Twitter

Tweet.

THE DATA42 PROGRAM SHOWS NOVARTIS’ INTENT TO GO BIG ON The data42 program shows Novartis’ intent to go big on data and digital. Novartis is betting on both human inquisitiveness and computer expertise to harness the wealth of its digital research and development platform, data42. Although artificial intelligence has been around for decades, recent developments in the realm of deep

learning have

PROFESSIONAL PRACTICES POLICY (P3) Novartis Global Policy Professional Practices Policy (P3) Novartis Global Policy March 1st, 2018 Version GIC 102.V1.EN

NOVARTIS

Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients

worldwide.

NOVARTIS PROVIDES UPDATE ON USE AND SAFETY OF BEOVU® IN March 02, 2020. As of March 2, 2020, more than 57,000 Beovu® (brolucizumab) vials for injection have been shipped to prescribing physicians in the US 1.To date, the safety data continue to support a favorable benefit-risk profile for Beovu 2,3.. Beovu is approved for the treatment of wet age-related macular degeneration (wet AMD) by the US Food & Drug Administration (FDA), the European

OPHTHALMOLOGY

Learn how innovative ophthalmology research at Novartis is producing therapies that treat retina diseases, glaucoma, presbyopia, dry eye, ocular surface diseases, other external eye diseases and inherited

retinal diseases.

IMMUNOLOGY & DERMATOLOGY Novartis is a global leader in immunology and dermatology. We are transforming the lives of people living with immunologic diseases, focusing on specialty dermatology, rheumatology, autoinflammatory, transplant, and specialty liver diseases where there remain high unmet

medical needs.

NOVARTIS ANNOUNCES POSITIVE RESULT OF PHASE III STUDY WITH Phase III VISION study with 177 Lu-PSMA-617 met both primary endpoints, significantly improving overall survival (OS) and radiographic progression-free survival (rPFS) in patients with PSMA-positive metastatic castration-resistant prostate cancer 1; VISION trial findings to be presented at upcoming medical meeting, with regulatory submissions in the US and EU anticipated in 2021 INVESTIGATOR-INITIATED TRIALS / STUDIES Novartis is committed to supporting Investigator Initiated Trials (IITs) as a part of the drug discovery and development process. Scientific research that is produced by qualified third-party investigators is key to complementing Novartis-sponsored research to help better understand the benefit/risk profile of our therapies as well as explore new opportunities to address unmet HOMEPAGE | NOVARTIS BIOME The Novartis Biome was created as a bridge to help our partners become an extension of our own teams, working with us as easily and productively as possible to jointly innovate and co EXECUTIVE DIRECTOR, GLOBAL NEW PRODUCTS- OPTHALMOLOGY 4.3 million patients were served by our Ophthalmology group in 2018. We are Novartis. Join us and help reimagine medicine The Executive New Products Director is a Global role serving as a core member of one or more Global Program Teams (GPT) for Novartis molecules in clinical development. He or she SECURITY OPERATIONS EXPERT 25! Information Security Tools! Would you like to have hands-on experience in these industry leading security products? Join our awesome Security Operations Automation Team! In this role you will contribute to the day-to-day management of a set of systems, tools or applications, ensuring their

BASE E12 - NOVARTIS

Metis. If you are using a basic mobile phone then click one of the below links to download the application. For MobileE12.jad. For

MobileE12MIDP1.jad

Close

* Skip to main navigation * Skip to main content

* Skip to Footer

Google Tag Manager

* Navigate Novartis

* Patients & Caregivers * Healthcare Professionals

* Media

* Investors

* Partners

* Society & ESG

* Job Seekers

* Coronavirus

* Global

* Novartis site directory * Our Company show submenu for Our Company

* Our Leadership

* Board of Directors * Executive Committee of Novartis

* Our Approach

* Strategy

* Corporate Responsibility * Diversity & Inclusion

* Partnering

* Culture and Values

* Our Business

* Global Product Portfolio * Innovative Medicines * Novartis Pharmaceuticals

* Novartis Oncology

* Sandoz

* Media

* Newsroom

* News Archive

* Multimedia Resources * Subscribe to Updates

* Investors

* Event Calendar

* Financial Data

* Share Data & Analysis * Shareholder Information * Environmental, Social & Governance * Our Focus show submenu for Our Focus

* Disease Areas

* Cancer

* Cardiovascular, Renal & Metabolism * Immunology & Dermatology

* Ophthalmology

* Neuroscience

* Respiratory

* Platforms and Technology * Artificial Intelligence * Cell & Gene Therapy

* Novartis Stories

* Discovery

* From Our Labs

* Access to Healthcare * Patient Perspectives * People and Culture * Our Impact show submenu for Our Impact * Building Trust with Society * Corporate Responsibility

* Ethical Standards

* Access

* Environmental Sustainability

* Global Health

* Malaria

* Sickle Cell Disease

* Chagas Disease

* Leprosy

* Novartis Foundation * ESG Performance and Reporting

* Materiality

* Environment, Social and Governance * Transparency and Disclosures * Positions on Key Topics * Statements on Key Issues * Our Science show submenu for Our Science * Research & Early Development * Novartis Institutes for BioMedical Research * Research Disease Areas

* Postdoc Program

* Open Source Science * Drug Development at Novartis * Global Clinical Pipeline * Translational Medicine * Novartis Clinical Trials * Global Product Portfolio

* Science Stories

* Discovery

* From Our Labs

* Careers show submenu for Careers

* Your Career

* Novartis Career Search * Careers in Digital * Careers in Research * Careers in Procurement * Careers in Health, Safety & Environment * Working at Novartis * Diversity & Inclusion * Culture and Values * Corporate Responsibility

* Career Programs

* Our Career Programs * Students and Scholars * Novartis Quantitative Sciences Hackathon

Search

NOVARTIS HOME

At Novartis, we are reimagining medicine CORONAVIRUS DISEASE (COVID-19) UPDATES Novartis is responding to the coronavirus situation with safety of associates and patients globally our primary concern. We are also supporting communities, contributing to research efforts and keeping generic medicine prices stable.

Learn More

ENVIRONMENTAL, SOCIAL AND GOVERNANCE (ESG) INDEX Novartis aims to report comprehensively and transparently about ESG topics. We have created the Novartis ESG Index to signpost where our key disclosures can be found across our publications and channels.

Read More

ANNUAL REVIEW 2019

The Annual Review explains who we are and what we do, and highlights our progress against the company’s five strategic priorities in

2019.

Learn More

Latest News

*

Mar 19, 2020

NOVARTIS RECEIVES APPROVAL FROM JAPANESE MINISTRY OF HEALTH, LABOUR AND WELFARE FOR ZOLGENSMA® THE ONLY GENE THERAPY FOR PATIENTS WITH SPINAL MUSCULAR ATROPHY (SMA)

*

Mar 18, 2020

NOVARTIS ANNOUNCES NEJM PUBLICATION OF THREE PIVOTAL TRIALS SHOWING DURABLE AND POTENT EFFICACY OF INCLISIRAN, AN INVESTIGATIONAL FIRST-IN-CLASS SIRNA CHOLESTEROL-LOWERING THERAPY

*

Mar 17, 2020

NOVARTIS ANNOUNCES BROAD RANGE OF INITIATIVES TO RESPOND TO COVID-19 PANDEMIC; CREATES USD 20 MILLION GLOBAL FUND TO SUPPORT IMPACTED

COMMUNITIES

*

Mar 03, 2020

INTERNATIONAL RESEARCH PARTNERSHIP AND EDCTP TO INVEST €44M IN NEXT-GENERATION ANTIMALARIALS TO COMBAT DRUG-RESISTANT MALARIA IN

AFRICA

Media releases

Novartis on Twitter

@Novartis

_46 min 25 sec_ ago

RT @VasNarasimhan: 11 years ago I helped lead efforts to find a vaccine during the H1N1 pandemic­, and it reshaped how I view humanity… https://t.co/sgtlAIhCjq

Follow Us

@Novartis

_1 day 1 hour_ ago

RT @VasNarasimhan: We are dealing with an extraordinary public health crisis that’s hitting our communities in unprecedented ways and… https://t.co/FOHle6PkMr

Follow Us

@Novartis

_1 month 2 weeks_ ago Learn how Advanced Accelerator Applications is using #NuclearMedicine to treat diseases like #Cancer.

Follow Us

INTERNATIONAL WOMEN’S DAY 2020 To celebrate International Women’s Day we explore how an inclusive environment that values unique and curious minds helps inspire Jessica, Simone and Maryam every day.

Learn More

CELL & GENE THERAPY AT NOVARTIS We are reimagining medicine to power breakthrough innovation in cell

and gene therapy.

Learn More

NOVARTIS GLOBAL

*

NAVIGATE NOVARTIS

* Patients & Caregivers * Healthcare Professionals

* Investors

* Media

* Society & ESG

* Partners

*

CONTACT US

* Global Contacts

* Office Locations

* For Investors

* For Media

*

ABOUT NOVARTIS

* Our Company

* Our Focus

* Our Impact

* Our Science

* Our Stories

*

OUR PORTFOLIO

* Global Product Portfolio * Global Clinical Pipeline

*

CAREERS

* Career Search

SUBSCRIBE TO NOVARTIS

* twitter

* linkedin

* youtube

* facebook

* instagram

Novartis Site Directory

� 2020 Novartis AG

* Terms of Use

* Privacy Policy

* Contact Us

* Site Map

This site is intended for a global audience. THIS WEBSITE INTENDS TO USE COOKIES TO IMPROVE THE SITE AND YOUR EXPERIENCE. BY CONTINUING TO BROWSE THE SITE YOU ARE AGREEING TO ACCEPT OUR USE OF COOKIES. IF YOU REQUIRE FURTHER INFORMATION AND/OR DO NOT WISH TO HAVE COOKIES PLACED WHEN USING THE SITE, VISIT ABOUT

COOKIES PAGE.

OK, I agree

Facebook Twitter Google+ Pinterest Email LinkedIn Google Gmail WhatsApp AIM Amazon Wish List AOL Mail App.net Baidu Balatarin BibSonomy Bitty Browser Blinklist Blogger Post BlogMarks Bookmarks.fr Box.net BuddyMarks Buffer Care2 News CiteULike Delicious Design Float Diary.Ru Diaspora Digg diHITT Diigo DZone Evernote Fark Flipboard Folkd FriendFeed Google Bookmarks Hacker News Hatena Instapaper Jamespot Kakao Kindle It Line LiveJournal Mail.Ru Mendeley Meneame Mixi Netlog Netvouz NewsTrust NewsVine NUjij Odnoklassniki Outlook.com Pinboard Plurk Pocket Print PrintFriendly Protopage Bookmarks Pusha Qzone Rediff MyPage Renren Segnalo Sina Weibo SiteJot Slashdot Springpad Stumpedia Svejo Symbaloo Feeds Tuenti Twiddla TypePad Post Viadeo VK Wanelo Webnews Wykop XING Yahoo Bookmarks Yahoo Mail Yahoo Messenger Yoolink YouMob Yummly ____

AddToAny

Facebook Twitter Google+ Pinterest Email LinkedIn Google Gmail AOL Mail Outlook.com Yahoo Mail Any email

Email app

More…